Austin, Texas native Dr. Jennifer Walden is a fellowship-trained, Board Certified Plastic Surgeon. After several years in New York, Dr. Walden recently relocated back to her Texas roots so her twin sons Max and Houston could be raised around family and read full article.
Dr. Walden is an active member of the American Society of Plastic Surgeons. She also serves as a spokesperson for them and American Society of Aesthetic Plastic Surgery.
While in New York, Dr. Walden completed a fellowship at the prestigious Manhattan Eye, Ear and Throat Hospital. She later became an Attending Plastic Surgeon. She also served as a Clinical Surgery Instructor at the New York University’s Langone Medical Center. After making the move back to Texas, Dr. Walden opened the Walden Cosmetic Surgery Center. She also has privileges at Hill Country Memorial Hospital and Westlake Medical Center.
Dr. Walden has no qualms about succeeding in a field where women make up only about ten percent. The state of Texas has 12 plastic surgeons. Despite those statistics, Dr. Walden has always remained at the top of her game and eager to help others who are in need of a better self-image and learn more about Walden.
Dr. Walden was born and raised in Austin Texas. After graduating from the University of Texas, she was waitlisted until an opening came up at The University of Texas Medical Branch in Arlington. She graduated at the top of her class. Dr. Walden says she benefitted from working alongside some of the top plastic surgeons in the U.S., including Dr. Sherill Alston, whom she considers a personal mentor.
Dr. Walden has been recognized as a Texas Super Doctor in 2013, 2014, and 2016.
More Visit: https://reviews.birdeye.com/dr-jennifer-walden-md-148219362260598
Foresite Capital is a healthcare progression equity enterprise. They endeavor in the provision of growth funding to developing healthcare leaders. Healthcare organizations providing disruptive products enjoy the growth capital, regardless of whether they are in the public or private markets. Recently, the San Francisco-based firm announced Ph.D. Molly as a venture partner. Fascinatingly, Dr. Molly brings with him an experience of over fifteen years in the pharmacological and genomic research expansion. Jim Tananbaum, Foresite Capital’s CEO and managing director, expressed great confidence in Dr. Molly’s incredible experience and leadership record. Jim acknowledges the resourcefulness of Molly, and the much they expect her impact the expansion of their horizons.
Jim Tananbaum’s Efforts Awarded Through Entry in the Forbes’ Midas 2017 List
Jim boasts of getting named among other 100 best venture stockholders. He has featured in the list for three years in a row. The CEO and founder of Foresite Capital celebrates over two decades of exceptional experience in the healthcare business and investing industries. Jim concentrates his energy and proficiency on opportunities bending towards calculated, functional, and economic opportunities. For over twenty-five years, he has impacted the healthcare franchises in nearly all the sectors. Visit LinkedIn for details.
Jim also co-founded GelTex Pharmaceuticals, which later sold for $1.6 billion. Before its sale, GelTex had pioneered two drugs that did quite well in the pharmaceutical industry. The highly educated healthcare mogul possesses excellent knowledge of his specialty. He is an alumnus of Yale University where he pursued BS/BSEE degrees. Jim also holds an M.D and M.B.A earned from Harvard University. He also went further to study for an M.S from Massachusetts Institute of Technology. Mr. Tananbaum unifies his academic excellence with the outstanding experience, to bring perfect solutions to the challenges ailing the healthcare sector. More details can be found on his Crunchbase profile.
Forbes prepares the Midas list by partnering with TrueBridge Capital Partners. They engage the public platforms when seeking to collect data. They then calculate a ranking for every of those enterprises. The responsible firms combine several factors before concluding that an individual should feature in the list. Their metric and deal count also help them a great deal in determining the enterprise capitalists’ position.
See more: http://pelotontherapeutics.com/bod-jim-tananbaum/
Check out his Facebook profile